Kole DeGolier
banner
koledegolier.bsky.social
Kole DeGolier
@koledegolier.bsky.social
Ph.D. | Immunology
Postdoctoral Research Fellow
Lab of James Scott-Browne, Ph.D.
National Jewish Health, Denver, CO
Cancer immunotherapy, immunology, epigenetic mechanisms controlling T cell fate
Reposted by Kole DeGolier
No functional NIH…no US scientists that spend their days making discoveries that save lives and drive US innovation and economic growth. This will negatively impact all Americans.
No study section...no grant reviews
No grant reviews...no grants awarded
No grants awarded...no research
No research...no functional NIH
All NIH study sections canceled indefinitely. This will halt science and devastate research budgets in universities.
January 22, 2025 at 11:17 PM
Reposted by Kole DeGolier
Yes. Exactly. One of (if not THE) best ROI for any govt spending.
Scientific advancements aside, this is economically irresponsible

Every $1 spent by NIH generates $2.46

For example, in 2023, $47B in NIH spending generated ~$93B

Halting NIH spending will LOSE the US a lot of money (and talent)
January 23, 2025 at 2:16 AM
I am thrilled to share my first-ever first author publication in Nature Immunology as my first post on Bluesky! Huge thanks to everyone who contributed to this work! See comments for more.

#celltherapy #immunology #immunotherapy #CARTcells

www.nature.com/articles/s41...
Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response - Nature Immunology
Here, Fry and colleagues examine the impact of antigen experience on subsequent CD8+ CAR T cell activity during the antileukemia response and show that RUNX2 overexpression enhances antitumor activity...
www.nature.com
January 2, 2025 at 10:45 PM